Chevron Corp vs Twist Bioscience Corp — how do they compare? Chevron Corp trades at $196 (market cap $385.77B), while Twist Bioscience Corp trades at $125.49 (market cap $7.72B). The key difference: Chevron Corp is far larger — about 50× Twist Bioscience Corp's market cap, and Chevron Corp pays a 3.62% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| CVX | TWST | |
|---|---|---|
Market Cap | $385.77B | $7.72B |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $124.88 |
52-Week Low | $146.72 | $24.16 |
Enterprise Value | $414.31B | $7.65B |
Dividend Yield | 3.62% | — |
Signals from Pluang's Aura AI — not financial advice
CVX trades at $194.9, up 4.47% today, with a bullish technical signal and strong analyst support. Recent earnings consistently beat expectations, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and 12.25% ROE, supported by a $13.8 billion investment in Argentina's Vaca Muerta shale project announced on June 2, 2026 (Reuters).
Outlook remains positive with a consensus price target of $214.25, implying 10% upside. Risks include declining revenue from $184.43B in 2025 and exposure to volatile oil prices, but high oil prices and strategic expansions provide growth catalysts. The stock offers a steady dividend of $1.78 per half-year.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →